Differential effects of UCN-O1, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole

Anti-Cancer Drugs

Volumn 10, Issue 1, 1999, Pages 67-78

  Akiyama, Tadakazu ^a   Shimizu, Makiko ^a   Okabe, Masami ^a   Tamaoki, Tatsuya ^a   Akinaga, Shiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

CDC2; Cell cycle; CGP 41 251; Cyclin B1; Staurosporine; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CYCLIN B1; MIDOSTAURIN; NOCODAZOLE; PROTEIN KINASE C INHIBITOR; STAUROSPORINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL SYNCHRONIZATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

EID: 0032988411     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199901000-00009     Document Type: Article

References (53)

1. 2+ dependent protein kinase. Biochem Biophys Res Commun 1986; 135: 397-402.
2. Harris W, Wilkinson SE, Nixon JS. Recent developments in protein kinase C inhibitor. Exp Opin Ther Patents 1997; 7: 63-8.
3. Lush RM, Senderowicz A, Figg WD, Headlee D, Inoue K. Sausville EA. Surprising pharmacokinetics of UCN-01 in patients with refractory neoplasms may be due to high degree of protein binding. Proc Am Ass Cancer Res 1997; 38: 600.
4. MacDonald AC, Propper D, King D, et al. Phase I and pharmacokinetic study of CGP 41251, an inhibitor of protein kinasc C. Proc Am Soc Clin Oncol 1997; 16: 212a.
5. Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H. UCN-01, a selective inhibitor of protein kinasc C from Streptomyces. J Antibiol 1987; 40: 1782-4.
6. Takahashi I, Saitoh Y, Yoshida M, et al. UCN-01 and UCN-02, a new selective inhibitors of protein kinase C. II. Purification, physiochemical properties, structural determinations, and biological activities. J Antibiol 1989; 42: 571-6.
7. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991; 51: 4888-92.
8. Akinaga S, Nomura K, Gomi K, Okabe M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 1993; 32: 183-9.
9. Akinaga S, Nomura K, Gomi K, Okabe M. Synergistic antitumor effect of UCN-01, a protein kinase (C) inhibitor, combined with various anti-cancer agents. Proc Am Ass Cancer Res 1992; 33: 514.
10. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ. Cell cycle arrest and inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 1993; 53: 2081-6.
11. Akinaga S, Nomura K, Gomi K, Okabe M. Effect of UCN-01, a selective inhibitor of protein kinase, C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother Pharmacol 1994; 33: 273-80.
12. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01, 7-hydroxl-staurosporine, inhibits kinase activity of cyclin-dependent kinase and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung carcinoma cell line. Biochem Biophys Res Commun 1996; 219: 778-83.
13. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinase 1 and 2. Cell Growth Different 1995; 6: 927-36.
14. Shao R-G, Shimizu T, Pommier Y. 7-hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. Exp Cell Res 1997; 234: 388-97.
15. Meyer T, Regenass U, Fabbro D, et al. A derivative of stauro-sporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer 1989; 43: 851-6.
16. Utz I, Hofer S, Regenass U, et al. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int J Cancer 1994; 57: 104-10.
17. Sedlak J, Hunakova L, Duraj J, Chorvath B, Novotny L. Effects of protein kinase C selective inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines. Anti-Cancer Drugs 1995; 6: 70-6.
18. Ikegami Y, Yano S, Nakao K. Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Jpn J Pharmacol 1996; 70: 65-72.
19. Ikegami Y, Yano S, Nakao K. Effects of the new selective protein kinasc C inhibitor 4′-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells. Arzneim-Forsch/Drug Res 1996; 46(I): 201-4.
20. 2 block caused by staurosporine, a potent inhibitor of protein kinases. Exp Cell Res 1991; 192: 122-7.
21. 1 phase of the cell cycle. Proc Natl Acad Sci USA 1991; 88: 7580-4.
22. Bruno S, Ardelt B, Skierski JS, Traganos F, Darzynkiewicz Z. Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res 1992; 51: 470-3.
23. 2 and on cytokinesis. J Cell Physiol 1994; 158: 535-14.
24. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and CDK inhibitors: Implications in cell cycle control and cancer. Eukaryotic Gene Expression 1995; 5: 127-56.
25. 1 arrest at two points: effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells. Cancer Res 1994; 54: 5959-63.
26. 1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc Natl Acad Sci USA 1996; 93: 5941-6.
27. 1 arrest is associated with the induction and accumulation of cyclin-dependent kinase inhibitors. Cell Growth Different 1996; 7: 1305-13.
28. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdil in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997; 57: 1495-501.
29. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1992; 61: 441-70.
30. Watanabe N, Broome M, Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 1995; 14: 1878-91.
31. cdc2-cyclin B complex by the human WEE 1 tyrosine kinase. Science 1992; 257: 1955-7.
32. cdc2. Cell 1991; 67: 197-211.
33. cdc25 is a nuclear protein required for the initiation of mitosis in human cells. Proc Natl Acad Sci USA 1991; 88: 10500-4.
34. Murray AW, Solomon MJ, Kirschner MW. The role of cyclin synthesis and degradation in the control of maturation promoting factor activity. Nature 1989; 339: 280-6.
35. Felix MA, Labbe JC, Doree M, Hunt T, Karsenti E. Triggering of cyclin degradation of amphibian eggs by cdc2 kinase. Nature 1990; 346: 379-82.
36. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature 1991; 349: 132-8.
37. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 580-685.
38. cdc2like kinases. Biochem Biophys Res Commun 1992; 184: 80-5.
39. Tam SW, Schlegel R. Staurosporine overrides checkpoints for mitotic onset in BHK cells. Cell Growth Different 1992; 3: 811-7.
40. Lorca T, Labbe JC, Devault A, et al. Dephosphorylation of cdc2 on threonine 161 is required for cdc2 kinase inactivation and normal anaphase. EMBO J 1992; 11: 2381-90.
41. cdc2 inhibitory kinases. Mol Biol Cell 1994; 5: 989-1001.
42. Kumagai A, Dunphy WG. Regulation of the cdc25 protein during the cell cycle in Xenopus extracts. Cell 1992; 70: 139-51.
43. Courage C, Snowden R, Gescher A. Differential effects of Staurosporine analogues on cell cycle, growth and viability in A549 cells. Br J Cancer 1996; 74: 1199-205.
44. Hall LL, Th'ng JPH, Guo XW, Teplitz RL, Bradbury EM. A brief staurosparine treatment of mitotic cells triggers premature exit from mitosis and polyploid cell formation. Cancer Res 1996; 56: 3551-9.
45. Sudakin V, Ganoth D, Dahan A, et al. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 1995; 6: 185-97.
46. cdc2. Cancer Res 1994; 54: 1412-4.
47. 2 cell cycle arrest in human keratinocytes by inhibitory phosphorylation of the cdc2 cell cycle kinase. Oncogene 1995; 11: 2151-6.
48. Poon RYC, Chau MS, Yamashita K, Hunter T. The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res 1997; 57: 5168-78.
49. Akinaga S, Nomura K, Gomi K, Okabe M. Diverse effects of indolocarbazole compounds on the cell cycle progression of ras-transformed rat fibroblast cells. J Antibiol 1993; 46: 1767-71.
50. Furnari B, Rhind N, Russel P. Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 1997; 277: 1495-7.
51. Kutnagai A, Dunphy WG. Purification and molecular cloning of P1x1, a cdc25-regulatory kinase from Xenopus egg extracts. Science 1996; 273: 1377-80.
52. Gong J, Ardert B, Traganos F, Darzynkieicz Z. Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines. Cancer Res 1994; 54: 4285-8.
53. Livnch E, Fishman DD. Linking protein kinase C to cell-cycle control. Eur J Biochem 1997; 248: 1-9.